share_log

SVB Leerink Maintains Outperform on Beam Therapeutics, Raises Price Target to $121

Benzinga Real-time News ·  May 10, 2022 01:17

SVB Leerink analyst Rick Bienkowski maintains Beam Therapeutics (NASDAQ:BEAM) with a Outperform and raises the price target from $118 to $121.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment